Recommendations for Incentivizing the Development of Vaccines, Diagnostics, and Therapeutics to Combat Antibiotic Resistance Image Access the Recommendation Report Recommendations for Incentivizing the Development of Vaccines, Diagnostics, and Therapeutics to Combat Antibiotic-Resistance* Executive Summary The global spread of antimicrobial resistance (AMR) is a pressing public health crisis, prompting international attention and recognition from world leaders. In its 2015 report, PACCARB identified the insufficiency of the current economic model to combat AMR and formed three working groups to develop recommendations for incentivizing the development of new products. These working groups focused on vaccines, diagnostics, and therapeutics/anti-infectives for both human and animal use. The report presents the findings and recommendations of the working groups, categorizing critical issues hindering product development into economic, research and development, regulatory, and behavioral areas. While prevention extends beyond vaccines and alternatives to antibiotics, this report primarily discusses prevention in the context of these interventions. In total, the working groups identified 45 critical issues and proposed 64 recommendations to address them, with PACCARB selecting the top 10 recommendations based on their potential impact on product development. Associated PACCARB Working Group This report was compiled by the Incentives for the Development of Products to Combat Antibiotic Resistance Working Group, and was voted on and approved by the full council at the 7th PACCARB Public Meeting on September 14, 2017. This working group was established in response to a Task Letter* from U.S. Department of Health and Human Services Secretary of Health and Human Services, Sylvia M. Burwell. *People using assistive technology may not be able to fully access information in these files. For assistance, contact the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria by emailing CARB@hhs.gov.